BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24689036)

  • 1. A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer.
    Taurin S; Nehoff H; van Aswegen T; Rosengren RJ; Greish K
    Biomed Res Int; 2014; 2014():323594. PubMed ID: 24689036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.
    Pritchard T; Rosengren RJ; Greish K; Taurin S
    J Drug Target; 2016; 24(5):441-9. PubMed ID: 26373825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
    Archibald M; Pritchard T; Nehoff H; Rosengren RJ; Greish K; Taurin S
    Int J Nanomedicine; 2016; 11():179-200. PubMed ID: 26811677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice.
    Enteshari S; Varshosaz J; Minayian M; Hassanzadeh F
    Invest New Drugs; 2018 Apr; 36(2):206-216. PubMed ID: 29177974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and
    Varshosaz J; Enteshari S; Hassanzadeh F; Hashemi-Beni B; Minaiyan M; Sadeghian-Rizi S
    Anticancer Agents Med Chem; 2018; 18(14):2017-2031. PubMed ID: 30205803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
    Zhang YX; Kong CZ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.
    Greish K; Nehoff H; Bahman F; Pritchard T; Taurin S
    J Drug Target; 2019 Sep; 27(8):903-916. PubMed ID: 30615483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer.
    Xian S; Parayath NN; Nehoff H; Giles NM; Greish K
    Anticancer Res; 2015 Sep; 35(9):4707-12. PubMed ID: 26254360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
    Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.
    Yang R; Ma YX; Chen LF; Zhou Y; Yang ZP; Zhu Y; Du XL; Shi JD; Ma HS; Zhang J
    Asian J Androl; 2010 Sep; 12(5):735-43. PubMed ID: 20473319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue Distribution and Systemic Toxicity Evaluation of Raloxifene Targeted Polymeric Micelles of Poly (Styrene-Maleic Acid)-Poly (Amide- Ether-Ester-Imide)-Poly (Ethylene Glycol) Loaded With Docetaxel in Breast Cancer Bearing Mice.
    Varshosaz J; Hassanzadeh F; Hashemi-Beni B; Minaiyan M; Enteshari S
    Recent Pat Anticancer Drug Discov; 2019 Nov; 14(3):280-291. PubMed ID: 31538904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease.
    Greish K; Taha S; Jasim A; Elghany SA; Sultan A; AlKhateeb A; Othman M; Jun F; Taurin S; Bakhiet M
    Clin Transl Med; 2017 Dec; 6(1):28. PubMed ID: 28770521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
    Ho TH; Nunez-Nateras R; Hou YX; Bryce AH; Northfelt DW; Dueck AC; Wong B; Stanton ML; Joseph RW; Castle EP
    Clin Genitourin Cancer; 2017 Apr; 15(2):196-202.e1. PubMed ID: 27771244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
    Toren P; Kim S; Johnson F; Zoubeidi A
    PLoS One; 2016; 11(4):e0152861. PubMed ID: 27046225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases.
    Daruwalla J; Nikfarjam M; Greish K; Malcontenti-Wilson C; Muralidharan V; Christophi C; Maeda H
    Cancer Sci; 2010 Aug; 101(8):1866-74. PubMed ID: 20579075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
    Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
    Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.
    Larson N; Greish K; Bauer H; Maeda H; Ghandehari H
    Int J Pharm; 2011 Nov; 420(1):111-7. PubMed ID: 21856392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
    Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
    Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.